Understanding Aortic Valve Disease: Stenosis, Regurgitation, and Your Treatment Options.

The aortic valve is the gateway between the left ventricle — the heart's main pumping chamber — and the aorta, the body's largest artery. A normal aortic valve has three thin, pliable leaflets (cusps) that open fully during systole to allow blood to exit the heart, then close tightly during diastole to prevent backflow. When disease disrupts this mechanism, the consequences can be life-threatening.

Aortic valve disease encompasses two primary pathologies:

• Aortic stenosis (AS) — narrowing of the valve opening that obstructs blood flow out of the heart. This is the most common valvular heart disease in the developed world, affecting 2-4% of adults over 65.
• Aortic regurgitation (AR) — incomplete closure of the valve allowing blood to leak back into the left ventricle during diastole. This volume overload progressively dilates and weakens the heart.

Some patients have combined aortic valve disease (mixed stenosis and regurgitation), and the clinical picture is determined by whichever lesion dominates hemodynamically. Additionally, approximately 1-2% of the population is born with a bicuspid aortic valve (two cusps instead of three), which accelerates degeneration and often presents 10-20 years earlier than tricuspid aortic valve disease.

Understanding the distinction between these pathologies is clinically important because they differ in mechanism, natural history, imaging assessment, and — critically — the timing and type of intervention. A treatment strategy that is appropriate for severe aortic stenosis may be entirely wrong for severe aortic regurgitation.

Aortic stenosis is classified by the 2020 ACC/AHA Guidelines for Valvular Heart Disease into four stages:

• Stage A (At Risk): Bicuspid valve or aortic sclerosis without hemodynamic obstruction. No intervention needed; serial monitoring recommended.
• Stage B (Progressive): Mild-to-moderate stenosis. Aortic valve area (AVA) >1.5 cm², mean gradient <20 mmHg. Annual echocardiographic surveillance.
• Stage C (Asymptomatic Severe): AVA ≤1.0 cm², mean gradient ≥40 mmHg, or peak velocity ≥4.0 m/s — but no symptoms. This is where clinical decision-making becomes complex. The 2020 guidelines give a Class IIa recommendation for intervention in asymptomatic severe AS when the left ventricular ejection fraction (LVEF) drops below 50%, or when an exercise test provokes symptoms or a fall in blood pressure.
• Stage D (Symptomatic Severe): Severe stenosis WITH symptoms (exertional dyspnea, angina, syncope, or heart failure). Intervention carries a Class I recommendation — the strongest level of evidence.

The three primary causes of aortic stenosis are:

• Calcific degeneration (degenerative AS) — the most common cause in patients over 65. Progressive calcium deposition stiffens the leaflets. Risk factors parallel atherosclerosis: age, hypertension, hyperlipidemia, diabetes, smoking, chronic kidney disease.
• Bicuspid aortic valve — the most common cause in patients under 65. The abnormal two-leaflet architecture creates turbulent flow that accelerates calcification. Often associated with ascending aortopathy requiring surveillance.
• Rheumatic heart disease — commissural fusion from prior rheumatic fever. Still common globally but rare in developed nations.

Diagnostic workup: Transthoracic echocardiography (TTE) is the primary diagnostic tool. Key parameters include peak aortic velocity, mean transvalvular gradient, aortic valve area (by continuity equation), and the dimensionless index. When echo findings are discordant — for example, a low gradient despite a small valve area — dobutamine stress echocardiography or cardiac CT with calcium scoring can resolve the ambiguity. The PARTNER and EVOLUT trials used a calcium score threshold (Agatston ≥2000 in men, ≥1200 in women) to confirm severe AS in low-flow, low-gradient cases.

Cardiac catheterization is reserved for cases where noninvasive testing is inconclusive, or when coronary anatomy needs assessment before intervention. CT angiography has become the standard for pre-procedural TAVR planning, providing precise aortic annular measurements, coronary height assessment, and vascular access evaluation.

Aortic regurgitation differs fundamentally from stenosis in both pathophysiology and management. Where stenosis creates pressure overload (the ventricle pushes against a narrowed opening), regurgitation creates volume overload (the ventricle must handle both its normal forward output and the regurgitant volume leaking back through the incompetent valve).

Causes of chronic aortic regurgitation include:

• Leaflet disease: Bicuspid valve prolapse, infective endocarditis (healed), rheumatic disease, myxomatous degeneration
• Aortic root disease: Annuloaortic ectasia, Marfan syndrome, Loeys-Dietz syndrome, ascending aortic aneurysm (sinotubular junction dilation pulling leaflets apart)

Acute aortic regurgitation — from endocarditis, aortic dissection, or trauma — is a surgical emergency. The left ventricle, which has not had time to dilate and compensate, faces sudden volume overload leading to acute pulmonary edema and cardiogenic shock. Urgent or emergent surgery is required.

Chronic AR follows a more indolent course. The left ventricle gradually dilates to accommodate the extra volume, and patients may remain asymptomatic for years or even decades. The challenge is identifying the tipping point — when irreversible ventricular dysfunction is imminent but has not yet occurred.

The 2020 ACC/AHA guidelines recommend intervention for chronic severe AR when:

• Symptoms develop (Class I)
• LVEF drops below 55% (Class I) — note this is a higher threshold than for AS, because the volume-loaded ventricle should be hyperdynamic; a "normal" LVEF of 55% in severe AR actually indicates early systolic dysfunction
• Left ventricular end-systolic dimension (LVESD) exceeds 50 mm or indexed LVESD >25 mm/m² (Class IIa)
• Progressive LV dilation on serial imaging (Class IIa)

Serial echocardiography is the cornerstone of surveillance. Patients with mild AR should be imaged every 3-5 years, moderate AR annually, and severe AR every 6-12 months. Any change in symptoms, exercise tolerance, or ventricular dimensions should trigger re-evaluation.

The choice between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) is one of the most consequential decisions in modern cardiac care. Over the past 15 years, a series of landmark randomized trials has reshaped how we approach this decision.

The evidence base:

• PARTNER 1 (2010-2011): Established TAVR as an option for inoperable patients (Cohort B) and demonstrated non-inferiority to surgery in high-risk patients (Cohort A). 5-year mortality was similar, but TAVR had more vascular complications and paravalvular leak; surgery had more bleeding and atrial fibrillation.
• PARTNER 2 / SAPIEN 3 (2016): Extended TAVR to intermediate-risk patients. TAVR was non-inferior to surgery at 2 years.
• PARTNER 3 (2019): In low-risk patients, TAVR with the SAPIEN 3 valve showed lower rates of the composite endpoint (death, stroke, rehospitalization) at 1 year. However, 5-year data showed convergence, and structural valve degeneration was more common in TAVR.
• EVOLUT Low Risk (2019): TAVR with the self-expanding CoreValve Evolut platform was non-inferior to surgery in low-risk patients at 2 years. Longer-term follow-up continues.

Current ACC/AHA guideline recommendations (2020, with 2025 focused update):

• Age ≥80 or STS-PROM ≥8%: TAVR preferred (Class I)
• Age 65-80: Shared decision-making between TAVR and SAVR, with Heart Team evaluation (Class I). Factors favoring SAVR: bicuspid valve, concomitant cardiac surgery needed, anatomy unfavorable for TAVR, long life expectancy (valve durability concerns). Factors favoring TAVR: high surgical risk, severe comorbidities, prior chest surgery, frailty.
• Age <65: SAVR remains preferred (Class I) due to superior long-term durability data and concerns about lifetime valve management with TAVR

The durability question remains the central unsettled issue. Surgical bioprosthetic valves have 15-20 year durability data. TAVR valves have robust data out to 5-8 years, with emerging 10-year data that is reassuring but not yet definitive. For a 55-year-old patient, this gap matters enormously — a second valve procedure may be needed during their lifetime. For an 80-year-old, it is largely irrelevant.

This is precisely the kind of decision where a second opinion adds the most value. A cardiac surgeon may emphasize durability and completeness of repair. An interventional cardiologist may emphasize recovery, procedural risk, and quality of life. Both perspectives are necessary, and the WhiteGloveMD Heart Team model ensures patients receive both.

When surgical aortic valve replacement is chosen, the next decision is valve type. Each option involves a fundamental tradeoff.

Mechanical valves (e.g., St. Jude Medical/Abbott bileaflet, ON-X):

• Durability: essentially unlimited — designed to last the patient's lifetime
• Require lifelong anticoagulation with warfarin (target INR 2.0-3.0 for aortic position), which carries 1-2% annual risk of major bleeding
• The ON-X valve is the only mechanical valve FDA-approved for lower INR targets (1.5-2.0) after 3 months, based on the PROACT trial
• Best suited for patients under 50 who can comply with anticoagulation monitoring and want to avoid reoperation
• ACC/AHA Class IIa recommendation for patients under age 50

Bioprosthetic (tissue) valves (e.g., Edwards Perimount, Medtronic Mosaic, LivaNova Crown):

• Made from bovine pericardium or porcine aortic valve tissue, mounted on a stent frame
• Do not require long-term anticoagulation (aspirin only after initial 3-6 months)
• Expected lifespan: 10-20 years depending on patient age at implant (younger patients degenerate valves faster due to more active calcium metabolism)
• May require reoperation or valve-in-valve TAVR when structural degeneration occurs
• ACC/AHA Class IIa recommendation for patients over age 50, and for patients of any age who cannot or prefer not to take warfarin

Newer options on the horizon:

• Sutureless and rapid-deployment valves (e.g., LivaNova Perceval, Edwards Intuity): Bioprosthetic valves designed for faster implantation, potentially enabling minimally invasive approaches. Early data suggests reduced cross-clamp times without sacrificing hemodynamics.
• Valve-in-valve TAVR: When a surgical bioprosthetic valve degenerates, a TAVR valve can often be deployed inside the failing prosthesis — avoiding redo open-heart surgery. This has become a critical consideration in the age-at-implant decision, as it provides a "bailout" for bioprosthetic valve failure.

The valve type decision should incorporate patient age, lifestyle, bleeding risk, compliance with monitoring, attitude toward reoperation, and — increasingly — the availability of valve-in-valve TAVR as a future option. Use our cost estimator to understand the financial implications of different valve strategies over your expected lifetime.

Bicuspid aortic valve (BAV) is the most common congenital cardiac anomaly, affecting 1-2% of the population with a 3:1 male predominance. BAV is not simply a valve with two leaflets — it is a genetic connective tissue disorder that affects the entire aorta.

Key clinical features of BAV:

• Accelerated valve degeneration: BAV patients develop hemodynamically significant stenosis or regurgitation 10-20 years earlier than patients with tricuspid valves. The abnormal flow dynamics across the asymmetric orifice create shear stress that accelerates fibrosis and calcification.
• Associated aortopathy: 20-40% of BAV patients develop ascending aortic dilation. This occurs independently of valve hemodynamics — even a normally functioning bicuspid valve is associated with aortic dilation. ACC/AHA guidelines recommend concomitant aortic replacement when the ascending aorta exceeds 4.5 cm in patients undergoing AVR for BAV, or prophylactic aortic replacement at 5.5 cm (5.0 cm with risk factors) even without valve disease.
• Familial screening: BAV has a heritable component with 9% first-degree relative prevalence. ACC/AHA guidelines recommend echocardiographic screening of first-degree relatives (Class I).

BAV and TAVR: Bicuspid anatomy was excluded from the major TAVR trials (PARTNER, EVOLUT). Observational registries (BAVARD, STS/ACC TVT Registry) show that TAVR in bicuspid valves is feasible but carries higher rates of paravalvular leak and may require more frequent post-dilation. The 2020 ACC/AHA guidelines recommend SAVR over TAVR for younger BAV patients, particularly when concomitant aortic surgery is needed. However, for older BAV patients with isolated stenosis and favorable anatomy, TAVR may be reasonable — this is an area where Heart Team discussion and individual assessment are essential.

Patients with bicuspid aortic valve disease represent one of the most common scenarios where a second opinion changes the treatment plan, precisely because the interplay between valve disease, aortopathy, patient age, and evolving technology creates genuine clinical uncertainty.

Understanding expected outcomes is essential for informed decision-making. Here is what the data shows:

Surgical AVR outcomes (STS National Database, 2024):

• Isolated AVR operative mortality: 1.5-2.5% (varies by risk profile)
• Stroke rate: 1.2-1.8%
• Median hospital stay: 5-7 days
• Return to normal activities: 6-8 weeks (full sternotomy), 3-4 weeks (minimally invasive)
• 10-year survival after AVR for severe AS: 60-70% (compared to 50% 2-year survival WITHOUT surgery for symptomatic severe AS)

TAVR outcomes (STS/ACC TVT Registry, 2024):

• 30-day mortality: 1.0-2.5% (varies by risk profile)
• Stroke rate: 1.5-2.5% at 30 days (higher than surgical AVR in some registries)
• New permanent pacemaker: 6-10% (SAPIEN 3), 15-25% (Evolut) — this remains the most significant TAVR-specific complication
• Median hospital stay: 1-3 days
• Return to normal activities: 1-2 weeks

Long-term management after aortic valve intervention:

• Annual echocardiography to assess prosthetic valve function
• Endocarditis prophylaxis for dental procedures (lifelong)
• If mechanical valve: warfarin with INR monitoring (home testing devices available)
• If bioprosthetic valve: monitor for structural degeneration, typically after 8-10 years. Annual echo sufficient early; increase to every 6 months once degeneration is detected.
• Blood pressure control — hypertension accelerates both native and prosthetic valve degeneration
• Cardiac rehabilitation — proven to improve functional capacity and quality of life after valve surgery

Your STS risk score provides a personalized prediction of your expected outcomes. WhiteGloveMD calculates STS PROM, EuroSCORE II, and AATS risk scores for every patient, providing cross-validated risk assessment.

Aortic valve disease management has become increasingly complex as the number of treatment options has expanded. Scenarios where expert second-opinion evaluation is particularly valuable include:

• Moderate AS with symptoms: Is the valve truly causing the symptoms, or is there another explanation? Stress echocardiography and advanced hemodynamic assessment can resolve this question.
• Asymptomatic severe AS: The guidelines permit intervention in selected asymptomatic patients, but the risk-benefit calculation is nuanced. Exercise testing, strain imaging, and biomarker assessment (BNP) can inform timing.
• Low-flow, low-gradient AS: This variant is diagnostically challenging and requires dobutamine stress echo and CT calcium scoring to confirm severity. Misdiagnosis is common.
• TAVR vs SAVR in the "gray zone" (ages 65-80): Neither option is clearly superior in this age range. Patient-specific anatomy, comorbidities, life expectancy, and preferences all influence the optimal choice.
• Bicuspid aortic valve with borderline aortopathy: Should the aorta be replaced concomitantly? What threshold is appropriate for this individual patient?
• Failed bioprosthetic valve: Redo surgery vs valve-in-valve TAVR. The decision depends on valve size, mechanism of failure, coronary risk, and patient risk profile.

WhiteGloveMD provides fellowship-trained Heart Team evaluation of these complex scenarios within 48 hours. Every case is reviewed by both a cardiac surgeon and an interventional cardiologist, ensuring that both surgical and catheter-based perspectives are represented in the recommendation. View our pricing or get started today.